Design a development plan and prepare a summary presentation for outlicensing. This will involve deciding which therapeutic indication is most appropriate for this compound, evaluate its competitive viability, estimate its commercial potential, prepare a target product profile, provide a marketing perspective of the intended consumer, design a clinical development plan with milestones and decision points and suggest potential remedies to liabilities.
Presentation should include about CT-189 Sigma1 Inhibitor for the Treatment of Castration-Resistant Prostate Cancer:
A total of 15 slides